Results 11 to 20 of about 4,599 (158)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case

Indian Journal of Radiology and Imaging, 2009
Arthropathy is a well known side effect of the iron chelator deferiprone (L1); however, the imaging findings in deferiprone-induced arthropathy are not well known.
Gyan Chand, Veena Chowdhury, A Manchanda, Sapna Singh   +3 more
doaj   +1 more source

Hematological Parameters in Beta Thalassemia Major Children [PDF]

Minia Journal of Medical Research, 2022
Background: Thalassemia is a hematological disorder that is caused by mutations in the genes that encode hemoglobin chains. Mutations in the β-globin gene are the most common cause of genetic disorders in humans, with 350 β-thalassemia variants ...
Zamzam Mohamed, Doaa Ismail, Samira Sayed, Arwa Aziz   +3 more
doaj   +1 more source

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

PLoS ONE, 2019
BACKGROUND:Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and
Nancy F Olivieri, Amir Sabouhanian, Brenda L Gallie   +2 more
doaj   +1 more source

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica, 2011
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and ...
Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, Aurelio Maggio   +19 more
doaj   +1 more source

Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases [PDF]

Trends in Pharmaceutical Sciences
Thalassemia is a genetic disease that significantly affects human health. The common treatment of thalassemia is the regular injection of red blood cell, which is associated with the accumulation of iron in different tissues of the body, and makes ...
Sara Sadeghian, Fateme Zare, Lotfollah Saghaie, Razieh Sabet   +3 more
doaj   +1 more source

Perbedaan Kadar Thyroid Stimulating Hormone dan Free Thyroxine pada Pasien Talasemia Β-Mayor dengan Kelasi Besi Deferasirox dan Deferiprone

Sari Pediatri, 2018
Latar belakang. Talasemia β Mayor merupakan kelainan herediter yang disebabkan gangguan produksi rantai globin. Transfusi rutin menyebabkan kelebihan besi yang tertimbun dalam jaringan sehingga menyebabkan kardiomiopati, gangguan liver, dan komplikasi ...
Aries - Krisbiyantoro, Harsono Salimo, Annang Giri Moelyo   +2 more
doaj   +1 more source

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]

F1000Research, 2023
Background Excess iron deriving from a chronic transfusion and dietary intake increases the risk for cardiac complications in β-thalassemia major patients.
Khairunnisa Khairunnisa, Heru Noviat Herdata, Eka Destianti Edward, Sulaiman Yusuf   +3 more
doaj   +1 more source

A pilot trial of deferiprone for neurodegeneration with brain iron accumulation

Haematologica, 2011
Deferiprone was shown to reverse iron deposition in Friedreich’s ataxia. This multi-center, unblinded, single-arm pilot study evaluated safety and efficacy of deferiprone for reducing cerebral iron accumulation in neurodegeneration with brain iron ...
Giovanni Abbruzzese, Giovanni Cossu, Manuela Balocco, Roberta Marchese, Daniela Murgia, Maurizio Melis, Renzo Galanello, Susanna Barella, Gildo Matta, Uberto Ruffinengo, Ubaldo Bonuccelli, Gian Luca Forni   +11 more
doaj   +1 more source

Synergistic Effects of Nanoemulsion and Deferiprone (1, 2 Dimethyl-3-Hydroxypyrid-4-One) on Multi-Drug Resistant Acinetobacter baumannii

Nano Biomedicine and Engineering, 2019
Nosocomial infections caused by Acinetobacter baumannii (A. baumannii) are exceedingly difficult to treat, particularly in immune-compromised patients. Nanoemulsions (NEs) are a distinctive category of disinfectants that have wide range of bactericidal ...
Karthikeyan Ramalingam, Valerie Lee
doaj   +1 more source

Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?

Biomolecules, 2022
The chelating thiol dimercaptosuccinate (DMSA) and the traditional agent D-penicillamine (PSH) are effective in enhancing the urinary excretion of copper (Cu) and lead (Pb) in poisoned individuals. However, DMSA, PSH, EDTA (ethylenediamine tetraacetate),
Jan O. Aaseth, Valeria M. Nurchi
doaj   +1 more source